Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

OBJECTIVES: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally. In China, sorafenib and oxaliplatin plus infusional-fluorouracil/leucovorin (FOLFOX4) are approved for the systemic treatment of advanced HCC. This study compared the cost-effectiveness of these therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Kruger, Eliza, Tan, Seng Chuen, Cheng, Shuqun, Wang, Nanya, Liang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076412/
https://www.ncbi.nlm.nih.gov/pubmed/30087583
http://dx.doi.org/10.1186/s12962-018-0112-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076412/
https://www.ncbi.nlm.nih.gov/pubmed/30087583
http://dx.doi.org/10.1186/s12962-018-0112-0

Ejemplares similares